Synthego Celebrates Supreme Court’s Ruling Invalidating Agilent's CRISPR Patents Synthego has welcomed the U.S. Supreme Court's decision to invalidate Agilent's patents on CRISPR technology, marking a significant moment for gene editing innovation.

Synthego Celebrates Supreme Court’s Ruling Invalidating Agilent's CRISPR Patents #USA #Redwood_City #CRISPR #Synthego #Agilent

Synthego Expands into Molecular Biology and Clinical Diagnostics Sector Synthego enters the molecular biology and clinical diagnostics market, providing high-quality reagents to accelerate diagnostic solutions and enhance global health outcomes.

Synthego Expands into Molecular Biology and Clinical Diagnostics Sector #USA #Redwood_City #CRISPR #Synthego #biotechrabbit

Synthego's Acquisition by Perceptive Advisors Marks a New Era in CRISPR Solutions Synthego has successfully completed its acquisition by Perceptive Advisors, paving the way for enhanced resources and innovation in CRISPR technology.

Synthego's Acquisition by Perceptive Advisors Marks a New Era in CRISPR Solutions #USA #Redwood_City #CRISPR #Synthego #Perceptive_Advisors

Synthego's Transition to Perceptive Advisors: A New Era in CRISPR Solutions Approaches Synthego has secured approval for its acquisition by Perceptive Advisors, paving the way for expanded CRISPR solutions and enhanced capabilities in biotechnology.

Synthego's Transition to Perceptive Advisors: A New Era in CRISPR Solutions Approaches #USA #CRISPR #Synthego #Redwood_City,_California #Perceptive_Advisors

Synthego Wins Patent Appeal, Invalidating Agilent's CRISPR Patents Synthego has successfully upheld a ruling that invalidates Agilent's CRISPR patents, paving the way for advancements in gene editing technologies and therapeutics.

Synthego Wins Patent Appeal, Invalidating Agilent's CRISPR Patents #USA #Redwood_City #CRISPR #Synthego #Agilent

Bay Area biotech company files for bankruptcy Synthego, a Redwood City biotech company that raised millions but saw its debt costs become insurmountable, declared bankruptcy this month.

Yet another reason why high #WallStreet valuations before a company has any viable product is problematic. It's almost like a hype, pump and dump scam. #Synthego #biotech
www.sfgate.com/tech/article...

Synthego Unveils GMP SpCas9 for Advanced Gene Editing Capabilities Synthego announces the launch of GMP SpCas9, a groundbreaking advancement in CRISPR technology, designed to facilitate gene editing for therapeutic purposes.

Synthego Unveils GMP SpCas9 for Advanced Gene Editing Capabilities #USA #Redwood_City #CRISPR_Technology #Synthego #GMP_SpCas9

Synthego and Vita Therapeutics Forge New Licensing Partnership to Enhance CRISPR Nuclease Applications Synthego and Vita Therapeutics announce a strategic licensing partnership integrating hfCas12Max CRISPR system into Vita's therapeutic programs, enhancing their development pipeline.

Synthego and Vita Therapeutics Forge New Licensing Partnership to Enhance CRISPR Nuclease Applications #USA #Redwood_City #Synthego #Vita_Therapeutics #hfCas12Max

Synthego and AstraZeneca Team Up for Revolutionary CRISPR Gene Editing Partnership Synthego forms a strategic alliance with AstraZeneca to license a novel CRISPR enzyme, enhancing therapeutic development for global researchers.

Synthego and AstraZeneca Team Up for Revolutionary CRISPR Gene Editing Partnership #USA #AstraZeneca #Redwood_City #CRISPR_solutions #Synthego